New Drugs 2020
Tracking # 20-794989
$10.00
There are no ratings for this course
Learn moreCourse overview
RX and NP For drugs reviewed in detail, provide the FDA approved indication state the recommended dose and discuss the evidence supporting the drug approval and its potential role in therapy. For drugs reviewed in detail describe significant warnings and precautions. Provide 2-3 patient counseling tips for each. For the briefly summarized drugs in Table 2 state the generic brand names dosage form FDA approved indication and safety concerns if discussed. Briefly describe the new targeted therapies for the treatment of NSCLC e g how they work role in therapy. Technicians For drugs reviewed in detail provide the FDA approved indication state the recommended dose and discuss the evidence supporting the drug approval and its potential role in therapy. For drugs reviewed in detail, describe significant warnings and precautions. Provide 2-3 patient counseling tips for each. For the briefly summarized drugs in Table 2, state the generic brand names, dosage form FDA approved indication and safety concerns, if discussed. Briefly describe the new targeted therapies for the treatment of NSCLC e g how they work role in therapy.
Subject areas
This course counts toward the state boards and subject areas below.
Arkansas State Board of Nursing
Certified Nurse Practitioner
Clinical Nurse Specialist
Registered Nurse
Registered Nurse Practitioner
District of Columbia Board of Nursing
Nurse Practitioner
Florida Board of Nursing
Advanced Practice Registered Nurse
Licensed Practical Nurse
Registered Nurse
Georgia Board of Nursing
Licensed Practical Nurse
Registered Professional Nurse
New Mexico Board of Nursing
Certified Nurse Practitioner
Certified Registered Nurse Anesthetist
Clinical Nurse Specialist
Registered Nurse
South Carolina Board of Nursing
Advanced Practice Registered Nurse
Licensed Practical Nurse
Registered Nurse
Disclosure statements
Dr. Chan reports no financial relationship with the manufacturer(s) or provider(s) of any commercial product(s) or service(s) that appear in this issue.